PL2709991T3 - Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii - Google Patents
Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopeniiInfo
- Publication number
- PL2709991T3 PL2709991T3 PL12786739T PL12786739T PL2709991T3 PL 2709991 T3 PL2709991 T3 PL 2709991T3 PL 12786739 T PL12786739 T PL 12786739T PL 12786739 T PL12786739 T PL 12786739T PL 2709991 T3 PL2709991 T3 PL 2709991T3
- Authority
- PL
- Poland
- Prior art keywords
- myelokathexis
- lymphocytopenia
- neutropenia
- cxcr4 antagonists
- whim syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486632P | 2011-05-16 | 2011-05-16 | |
| EP12786739.8A EP2709991B1 (en) | 2011-05-16 | 2012-05-15 | Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia |
| PCT/US2012/037970 WO2012158707A1 (en) | 2011-05-16 | 2012-05-15 | Use of cxcr4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2709991T3 true PL2709991T3 (pl) | 2021-04-06 |
Family
ID=81755014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12786739T PL2709991T3 (pl) | 2011-05-16 | 2012-05-15 | Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150030561A1 (https=) |
| EP (1) | EP2709991B1 (https=) |
| JP (1) | JP2014513727A (https=) |
| KR (3) | KR20140045411A (https=) |
| CN (1) | CN103596935A (https=) |
| BR (1) | BR112013029482A2 (https=) |
| ES (1) | ES2831049T3 (https=) |
| MX (1) | MX365242B (https=) |
| PL (1) | PL2709991T3 (https=) |
| RU (1) | RU2638802C2 (https=) |
| WO (1) | WO2012158707A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1879624B1 (en) | 2005-05-02 | 2011-09-21 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| US9419667B2 (en) | 2013-04-16 | 2016-08-16 | Skyworks Solutions, Inc. | Apparatus and methods related to conformal coating implemented with surface mount devices |
| US9375406B2 (en) * | 2014-09-30 | 2016-06-28 | Taigen Biotechnology Co., Ltd. | Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| PL3393468T3 (pl) * | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017223243A1 (en) * | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN110536966A (zh) * | 2016-09-08 | 2019-12-03 | 能源环境和技术研究中心O.A.,M.P. | 用于范可尼贫血患者的基因疗法 |
| CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
| BR112020020841A2 (pt) | 2018-04-11 | 2021-01-19 | Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus | Composições e métodos para transplante de célulastronco |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| EP4232058A1 (en) * | 2020-10-20 | 2023-08-30 | Eom Pharmaceuticals Inc. | Eom613 for treatment of covid-19 |
| CN113662937B (zh) * | 2021-10-09 | 2022-08-23 | 江苏省人民医院（南京医科大学第一附属医院） | Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途 |
| CN116675708A (zh) * | 2023-04-23 | 2023-09-01 | 华南师范大学 | 一类氧化响应的大环化合物、大环配合物及其应用 |
| WO2025122961A1 (en) * | 2023-12-08 | 2025-06-12 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| WO1999047158A2 (en) | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| EP1068357B2 (en) | 1998-03-30 | 2014-12-10 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| DE60042030D1 (de) | 1999-12-17 | 2009-05-28 | Genzyme Corp | Chemokinrezeptor-bindende heterocyclische verbindungen |
| US20070160574A1 (en) | 2000-04-12 | 2007-07-12 | Ahmed Merzouk | Design of CXC chemokine analogs for the treatment of human diseases |
| CA2335109A1 (en) | 2000-04-12 | 2001-10-12 | Chemokine Therapeutics Corporation | Cxcr4 agonist treatment of hematopoietic cells |
| DE60103052T2 (de) | 2000-05-09 | 2005-03-03 | The University Of British Columbia, Vancouver | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| CA2412436C (en) | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| AU2002211393B2 (en) | 2000-09-29 | 2007-06-28 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| WO2002094261A1 (fr) | 2001-05-24 | 2002-11-28 | Kureha Chemical Industry Company, Limited | Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote |
| ES2380009T3 (es) | 2001-07-31 | 2012-05-07 | Genzyme Global S.A.R.L. | Métodos para movilizar las células madre/progenitoras |
| US20030221931A1 (en) | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| WO2004020462A1 (ja) | 2002-08-27 | 2004-03-11 | Fujii, Nobutaka | Ｃｘｃｒ４拮抗薬およびその用途 |
| EP1608352B1 (en) | 2003-04-02 | 2009-12-30 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
| US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
| JP2008509928A (ja) | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
| WO2006095542A1 (ja) | 2005-03-04 | 2006-09-14 | Kureha Corporation | アミン系化合物を含む医薬組成物 |
| WO2007022385A2 (en) * | 2005-08-18 | 2007-02-22 | Novartis Ag | Use of cxcr4 binding molecules for the treatment of whim syndrome |
| CA2619828A1 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
| US20090221683A1 (en) * | 2005-10-18 | 2009-09-03 | Caritas St.Elizabeth Medical Center Of Boston, Inc | Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis |
| MX2008010895A (es) | 2006-02-24 | 2008-09-03 | Genzyme Corp | Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos. |
| EP2041067A4 (en) | 2006-07-11 | 2009-11-25 | Univ Emory | CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS |
| AU2007281090A1 (en) | 2006-08-02 | 2008-02-07 | Genzyme Corporation | Combination therapy |
| JP2010507567A (ja) | 2006-08-07 | 2010-03-11 | ジェンザイム・コーポレーション | 併用療法 |
| PL2132221T3 (pl) | 2007-02-28 | 2011-04-29 | Polyphor Ltd | Przyłączone do matrycy peptydomimetyki |
| WO2010008840A2 (en) | 2008-06-23 | 2010-01-21 | Research In Motion Limited | Method for delivering device and server capabilities |
| WO2010025416A1 (en) | 2008-08-29 | 2010-03-04 | Genzyme Corporation | Cxcr4 antagonists for kidney injury |
| JP2012516353A (ja) * | 2009-01-30 | 2012-07-19 | ジェンザイム・コーポレーション | 血液系悪性腫瘍を治療するための方法及び組成物 |
-
2012
- 2012-05-15 RU RU2013155601A patent/RU2638802C2/ru active
- 2012-05-15 BR BR112013029482A patent/BR112013029482A2/pt not_active IP Right Cessation
- 2012-05-15 PL PL12786739T patent/PL2709991T3/pl unknown
- 2012-05-15 JP JP2014511460A patent/JP2014513727A/ja not_active Withdrawn
- 2012-05-15 WO PCT/US2012/037970 patent/WO2012158707A1/en not_active Ceased
- 2012-05-15 EP EP12786739.8A patent/EP2709991B1/en active Active
- 2012-05-15 ES ES12786739T patent/ES2831049T3/es active Active
- 2012-05-15 CN CN201280024014.6A patent/CN103596935A/zh active Pending
- 2012-05-15 KR KR1020137033309A patent/KR20140045411A/ko not_active Ceased
- 2012-05-15 KR KR1020207003632A patent/KR20200016407A/ko not_active Ceased
- 2012-05-15 US US14/118,144 patent/US20150030561A1/en not_active Abandoned
- 2012-05-15 KR KR1020217023153A patent/KR20210094672A/ko not_active Ceased
- 2012-05-15 MX MX2013013308A patent/MX365242B/es active IP Right Grant
-
2020
- 2020-07-13 US US16/927,856 patent/US20210161859A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2709991A4 (en) | 2014-10-01 |
| ES2831049T3 (es) | 2021-06-07 |
| RU2013155601A (ru) | 2015-06-27 |
| RU2638802C2 (ru) | 2017-12-15 |
| KR20140045411A (ko) | 2014-04-16 |
| MX365242B (es) | 2019-05-28 |
| BR112013029482A2 (pt) | 2016-08-09 |
| US20210161859A1 (en) | 2021-06-03 |
| EP2709991B1 (en) | 2020-09-02 |
| JP2014513727A (ja) | 2014-06-05 |
| US20150030561A1 (en) | 2015-01-29 |
| CN103596935A (zh) | 2014-02-19 |
| KR20200016407A (ko) | 2020-02-14 |
| KR20210094672A (ko) | 2021-07-29 |
| MX2013013308A (es) | 2014-02-27 |
| EP2709991A1 (en) | 2014-03-26 |
| WO2012158707A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2709991T3 (pl) | Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii | |
| IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
| AP4017A (en) | Substituted triazolopyridines and their use as ttk inhibitors | |
| ZA201401117B (en) | Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof | |
| IL235246B (en) | Imidazothiadiazole and imidazopyrazine derivatives as protease-activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation | |
| IL253911A0 (en) | Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use | |
| EP2675469A4 (en) | COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | |
| IL234884A0 (en) | Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| IL235923A0 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof | |
| IL230705A0 (en) | Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| IL228433A0 (en) | Pyridopyrazine history and their use | |
| ZA201602084B (en) | Conformationally restrictred pi3k and mtor inhibitors | |
| PT2841087T (pt) | Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos | |
| PT2709991T (pt) | Uso de antagonistas de cxcr4 para tratar síndrome de whim, mielocatexia, neutropenia e linfocitopenia | |
| GB201207102D0 (en) | CRHR1 antagonists for use in the treatment of patients having CRH overactivity |